Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk

Ann Pharmacother. 2022 Apr;56(4):507-508. doi: 10.1177/10600280211036047. Epub 2021 Jul 30.

Authors

Xian Jie Cindy Chen¹, Diana Altshuler¹, Peter Spiegler², Shari B Brosnahan³

Affiliations

¹ New York University Langone Health, New York, NY, USA.
² New York University Long Island School of Medicine, New York, NY, USA.
³ New York University Grossman School of Medicine, New York, NY, USA.

PMID: 34330173
DOI: 10.1177/10600280211036047

No abstract available

Publication types

Letter
Comment

MeSH terms

Adrenal Cortex Hormones / adverse effects
Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
Respiratory Insufficiency*
SARS-CoV-2

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal, Humanized
tocilizumab